Leerink Partnrs Estimates Bruker's Q1 Earnings (NASDAQ:BRKR)

Bruker Co. (NASDAQ:BRKR - Free Report) - Analysts at Leerink Partnrs reduced their Q1 2025 earnings per share estimates for Bruker in a report released on Thursday, February 13th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of $0.41 per share for the quarter, down from their prior estimate of $0.54. The consensus estimate for Bruker's current full-year earnings is $2.69 per share. Leerink Partnrs also issued estimates for Bruker's Q2 2025 earnings at $0.61 EPS, Q3 2025 earnings at $0.72 EPS, Q4 2025 earnings at $0.98 EPS, FY2026 earnings at $3.12 EPS and FY2027 earnings at $3.60 EPS.

A number of other brokerages have also issued reports on BRKR. The Goldman Sachs Group upgraded shares of Bruker from a "sell" rating to a "neutral" rating and set a $60.00 price target on the stock in a research note on Thursday, December 5th. Guggenheim reissued a "buy" rating on shares of Bruker in a research report on Friday, January 17th. Wells Fargo & Company decreased their target price on Bruker from $78.00 to $75.00 and set an "overweight" rating for the company in a research note on Wednesday, November 6th. UBS Group started coverage on shares of Bruker in a research note on Tuesday, December 10th. They set a "neutral" rating and a $66.00 price target on the stock. Finally, Bank of America raised their price objective on Bruker from $78.00 to $80.00 and gave the stock a "buy" rating in a report on Friday, December 13th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $70.50.

Bruker Trading Up 2.7 %

Shares of BRKR traded up $1.38 during midday trading on Monday, hitting $52.92. 2,145,257 shares of the stock were exchanged, compared to its average volume of 1,638,396. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The firm has a market cap of $8.02 billion, a P/E ratio of 69.63, a P/E/G ratio of 2.07 and a beta of 1.16. Bruker has a 52-week low of $48.07 and a 52-week high of $94.86. The stock has a fifty day simple moving average of $56.98 and a 200 day simple moving average of $60.18.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%.

Hedge Funds Weigh In On Bruker

Institutional investors have recently bought and sold shares of the company. Gordian Capital Singapore Pte Ltd purchased a new position in Bruker during the fourth quarter worth about $234,000. EDENTREE ASSET MANAGEMENT Ltd boosted its stake in shares of Bruker by 11.2% in the fourth quarter. EDENTREE ASSET MANAGEMENT Ltd now owns 158,000 shares of the medical research company's stock valued at $9,262,000 after buying an additional 15,900 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Bruker by 17.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 356,969 shares of the medical research company's stock worth $20,926,000 after acquiring an additional 52,214 shares during the period. Voloridge Investment Management LLC raised its position in Bruker by 179.6% in the fourth quarter. Voloridge Investment Management LLC now owns 18,906 shares of the medical research company's stock worth $1,108,000 after acquiring an additional 12,145 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its holdings in Bruker by 406.1% in the fourth quarter. Two Sigma Advisers LP now owns 140,700 shares of the medical research company's stock valued at $8,248,000 after acquiring an additional 112,900 shares during the period. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.